Stocks · News reference
Bristol Myers Squibb (BMY) 2-year Phase 3 data shows Sotyktu maintains durable efficacy and safety in active psoriatic arthritis.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Bristol Myers announced positive two-year results from the POETYK PsA-2 study showing Sotyktu (deucravacitinib) maintained durable efficacy and consistent safety through week 104. The drug generated $156 million in H1 2026 revenues, up 24% year-over-year, with potential for further expansion into lupus and Sjögren's disease indications.
William Blair initiates Perspective Therapeutics (NYSE: CATX) at Outperform, citing its strong radiopharmaceutical platform.
AbbVie and Bristol Myers Squibb are compared as pharmaceutical investment options for 2026. AbbVie is recommended as the better buy due to its successful immunology franchise with Skyrizi and Rinvoq driving growth, diversification into aesthetics and neuroscience, and having navigated its patent cliff challenges. Bristol Myers Squibb, while cheaper on valuation metrics and maintaining strong profit margins, faces revenue stagnation, legal uncertainties from a Celgene acquisition lawsuit, and is still working through its own portfolio transition challenges.